The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2662-2667

  Reiter, Andreas ^a   Walz, Christoph ^a   Watmore, Ann ^b   Schoch, Claudia ^c   Blau, Ilona ^d   Schlegelberger, Brigitte ^e   Berger, Ute ^a   Telford, Nick ^f   Aruliah, Shilani ^g   Yin, John A ^h   Vanstraelen, Danny ⁱ   Barker, Helen F ^j   Taylor, Peter C ^j   O'Driscol, Aisling ^k   Benedetti, Fabio ^l   Rudolph, Cornelia ^e   Kolb, Hans Jochem ^c   Hochhaus, Andreas ^a   Helmann, Rüdiger ^a   Chase, Andrew ^m,n   Cross, Nicholas C P ^m,n   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Hamatologisch onkologische S   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^h MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ VIRGA JESSE HOSPITAL   (Belgium)

^j ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

^k WORTHING HOSPITAL   (United Kingdom)

^l UNIVERSITY HOSPITAL OF VERONA   (Italy)

^m SALISBURY DISTRICT HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; COMPLEMENTARY DNA; JANUS KINASE 2; MESSENGER RNA; PERICENTRIOLAR MATERIAL 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; CENTROSOME; CHRONIC LEUKEMIA; CLINICAL ARTICLE; ENZYME DEFECT; EOSINOPHILIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE AMPLIFICATION; GENE FUSION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ADULT; AGED; AMINO ACID SEQUENCE; AUTOANTIGENS; BASE SEQUENCE; CELL CYCLE PROTEINS; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 20144389913     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4263     Document Type: Article

References (31)

1. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
2. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
3. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998;18:84-7.
4. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998;92:1735-42.
5. Popovici C, Zhang B, Gregoire MJ, et al. The t(6:8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999;93:1381-9.
6. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 2000;95:1788-96.
7. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002;107:101-7.
8. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002;11:1391-7.
9. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor β. Acta Haematol 2002;107:113-22.
10. Cross NCP, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002;16:1207-12.
11. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
12. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med 2002;347:481-7.
13. Stewart K, Carstairs KC, Dube ID, Keating A. Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. Am J Hematol 1990;34:59-63.
14. Sohal J, Chase A, Mould S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer 2001;32:155-63.
15. Lupas A, Van Dyke M, Stock J. Predicting coiled coils from protein sequences. Science 1991;252:1162-4.
16. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;90:2535-40.
17. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-12.
18. Griesinger F, Podleschny M, Steffens R, et al. A novel BCR-JAK2 fusion gene is the result of a translocation (9;22)(p24;q11) in a case of CML. Blood 2000;96:352a.
19. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996;95:2-9.
20. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to Imatinib therapy. Blood 2003;102:3093-6.
21. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004;18:734-42.
22. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-45.
23. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2000. Bethesda (MD): National Cancer Institute; 2003.
24. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol 2002;118:1071-7.
25. Balczon R, Bao L, Zimmer WE. PCM-1, a 228-kD centrosome autoantigen with a distinct cell cycle distribution. J Cell Biol 1994;124:783-93.
26. Dammermann A, Merdes A. Assembly of centrosomal proteins and microtubule organization depends on PCM-1. J Cell Biol 2002;159:255-66.
27. Vizmanos JL, Novo FJ, Roman JP, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 2004;64:2673-6.
28. Corvi R, Berger N, Balczon R, Romeo G. RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. Oncogene 2000;19:4236-42.
29. Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev 2003;22:423-34.
30. Xie S, Wang Y, Liu J, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001;20:6188-95.
31. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379:645-8.